Evidence map›Paper›PMID 36362579›Full record

ArticleJournal of clinical medicine2022

Reduced Risk of Progression from Non-Severe to Severe COVID-19 in Hospitalized Dialysis Patients by Full COVID-19 Vaccination.

Mitsuru Ichii, Masafumi Kurajoh, Yujiro Okute, Yasutaka Ihara, Takumi Imai, Tomoaki Morioka, Katsuhito Mori, Tetsuo Shoji, Yoshihiro Tsujimoto, Takanobu Ubai and 1 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mitsuru IchiiDivision of Internal Medicine, Dialysis Center, Inoue Hospital, Suita 564-0053, Japan.
Masafumi KurajohDepartment of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.ORCID 0000-0002-2571-9375
Yujiro OkuteDivision of Internal Medicine, Dialysis Center, Inoue Hospital, Suita 564-0053, Japan.
Yasutaka IharaDepartment of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
Takumi ImaiDepartment of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
Tomoaki MoriokaDepartment of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.ORCID 0000-0002-2329-8191
Katsuhito MoriDepartment of Nephrology, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
Tetsuo ShojiDepartment of Vascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.ORCID 0000-0003-3953-0925
Yoshihiro TsujimotoDivision of Internal Medicine, Dialysis Center, Inoue Hospital, Suita 564-0053, Japan.
Takanobu UbaiDepartment of Urology, Inoue Hospital, Suita 564-0053, Japan.
Masanori EmotoDepartment of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) vaccination reduces the risk of progression to severe COVID-19 in the general population. To examine that preventive effect in dialysis patients, the association of vaccination status with severe COVID-19 progression was investigated in this retrospective observational study conducted from December 2020 to May 2022 of 100 such patients hospitalized for non-severe COVID-19 at Inoue Hospital (Suita, Japan). Fifty-seven were fully vaccinated, defined as receiving a COVID-19 vaccine second dose at least 14 days prior to the onset of COVID-19, while 43 were not. Among all patients, 13 (13.0%) progressed to severe COVID-19 with a median (interquartile range) time of 6 (2.5-9.5) days, while 87 (87.0%) were discharged after 11 (8-16) days. Kaplan-Meier analysis showed that fully vaccinated patients had a significantly lower rate of progression to severe COVID-19 (

Indexed as

COVID-19dialysis patientsfull vaccinationsevere progression

Identifiers

PMID36362579
PMCPMC9657170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.